Blog
RSS FeedPosted by Michael Wonder on 06 Dec 2024
NICE describes how weight loss drug tirzepatide will be rolled out
5 December 2024 - The medication will initially be offered only to those people with the highest clinical needs. ...
Posted by Michael Wonder on 06 Dec 2024
Does NICE’s “severity modifier” for assessing diseases need to change?
22 November 2024 - Breast cancer charities and patients are “devastated” that the drug Enhertu will not be available in ...
Posted by Michael Wonder on 06 Dec 2024
MHRA approves new diagnostic agent for adult patients showing signs of cognitive impairment for Alzheimer’s disease
27 November 2024 - The MHRA has approved the medicine flortaucipir (Tauvid), given to adults with memory problems so that doctors ...
Posted by Michael Wonder on 04 Dec 2024
Fedratinib dihydrochloride monohydrate for the treatment of adults with disease-related splenomegaly or symptoms in myelofibrosis
20 November 2024 - NICE has published final evidence-based recommendations on the use of fedratinib dihydrochloride monohydrate (Inrebic) for the ...
Posted by Michael Wonder on 30 Nov 2024
NICE responds to failure of talks to reach price agreement on Enhertu
19 November 2024 - Talks with the makers of Enhertu have ended without agreement, meaning guidance that does not recommend Enhertu ...
Posted by Michael Wonder on 27 Nov 2024
Sparsentan approved to treat adult patients with primary immunoglobulin A nephropathy
18 November 2024 - The MHRA has approved the medicine sparsentan (Filspari) to treat primary immunoglobulin A nephropathy. ...
Posted by Michael Wonder on 19 Nov 2024
Zilucoplan sodium for the treatment of patients with antibody positive generalised myasthenia gravis (revised draft guidance)
14 November 2024 - NICE has produced updated guidance on the use of zilucoplan sodium in the NHS in England. ...
Posted by Michael Wonder on 17 Nov 2024
Junshi Biosciences announces UK MHRA approval for marketing of toripalimab
16 November 2024 - Shanghai Junshi Biosciences announced that the UK MHRA has approved toripalimab (Loqtorzi) for the treatment of two ...
Posted by Michael Wonder on 17 Nov 2024
MHRA approves adapted Nuvaxovid JN.1 COVID-19 vaccine for adults and children aged 12 plus
15 November 2024 - The MHRA has approved an adapted version of the Nuvaxovid COVID-19 vaccine that targets the Omicron JN.1 ...
Posted by Michael Wonder on 16 Nov 2024
New study shows NICE advice support can reduce appraisal timelines by 3 months
14 November 2024 - Companies who receive scientific advice from our NICE Advice service may experience a faster path to guidance ...
Posted by Michael Wonder on 14 Nov 2024
Elafibranor for the treatment of patients with primary biliary cholangitis
14 November 2024 - NICE has published final evidence-based recommendations on the use of elafibranor (Iqirvo) for the treatment of ...
Posted by Michael Wonder on 14 Nov 2024
Teclistamab for the treatment of patients with relapsed and refractory multiple myeloma after three or more treatments (final guidance)
13 November 2024 - NICE has published final evidence-based recommendations on the use of teclistamab (Tecvayli) for the treatment of ...
Posted by Michael Wonder on 13 Nov 2024
Sanofi wins appeal in spat with NICE over Sarclisa
13 November 2024 - Sanofi has taken a small step towards potentially overturning a recent rejection by NICE for NHS ...
Posted by Michael Wonder on 13 Nov 2024
Alectinib hydrochloride for the adjuvant treatment of patients with ALK positive non-small-cell lung cancer
13 November 2024 - NICE has published final evidence-based recommendations on the use of alectinib hydrochloride for the adjuvant treatment ...
Posted by Michael Wonder on 11 Nov 2024
MHRA grants marketing authorisation for Balversa (erdafitinib) as monotherapy for the treatment of adults with unresectable or metastatic urothelial carcinoma (UC) harbouring susceptible FGFR3 genetic alterations who have previously received at least one line of therapy containing a PD-1 or PD-L1 inhibitor in the unresectable or metastatic treatment setting
6 November 2024 - Erdafitinib is the first and only bladder cancer therapy that targets FGFR3 alterations and has been ...